Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis

Journal of Affective Disorders

Volumn 124, Issue 3, 2010, Pages 228-234

  Bond, David J ^a   Lam, Raymond W ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bipolar disorder; Depression; Divalproex; Meta analysis; Randomized controlled trial

Indexed keywords

PLACEBO; VALPROATE SEMISODIUM;

BIPOLAR DEPRESSION; CLINICAL TRIAL; DATA EXTRACTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTICONVULSANTS; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77953693323     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.11.008     Document Type: Review

References (33)

1. Baron M., Gershon E.S., Rudy V., Jonas W.Z., and Buchsbaum M. Lithium carbonate response in depression: prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch. Gen. Psychiatry 32 (1975) 1107-1111
2. Blanco C., Laje G., Olfson M., Marcus S.C., and Pincus H.A. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am. J. Psychiatry 159 (2002) 1005-1010
3. Calabrese J.R., Suppes T., Bowden C.L., Sachs G.S., Swann A.C., McElroy S.L., Kusumakar V., Ascher J.A., Earl N.L., Greene P.L., and Monaghan E.T. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J. Clin. Psychiatry 61 (2000) 841-850
4. Calabrese J.R., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.P., Montgomery P., Ascher J., Paska W., Earl N., and DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64 (2003) 1013-1024
5. Calabrese J.R., Keck P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. Am. J. Psychiatry 162 (2005) 1351-1360
6. Davis L.L., Bartolucci A., and Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord. 85 (2005) 259-266
7. DeCastro M., Nankova B.B., Shah P., Patel P., Mally P.V., Mishra R., and La Gamma E.F. Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-dependent signaling pathway. Brain Res. Mol. Brain Res. 142 (2005) 28-38
8. Fahn S. Post-anoxic action myoclonus: improvement with valproic acid. NEJM 299 (1978) 313-314
9. Fukuchi M., Nii T., Ishimaru N., Minamino A., Hara D., Takasaki I., Tabuchi A., and Tsuda M. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci. Res. 65 (2009) 35-43
10. Geddes J.R., Calabrese J.R., and Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry 194 (2009) 4-9
11. Ghaemi S.N., Hsu D.J., Thase M.E., Wisniewski S.R., Nierenberg A.A., Miyahara S., and Sachs G. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr. Serv. 57 (2006) 660-665
12. Ghaemi S.N., Gilmer W.S., Goldberg J.F., Zablotsky B., Kemp D.E., Kelley M.E., Bauer A.D., Fleck J., Filkowski M.M., Stan V.A., and Dunn R.T. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J. Clin Psychiatry 68 (2007) 1840-1844
13. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., and Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 161 (2004) 1537-1547
14. Goodwin F.K., Murphy D.L., and Bunney Jr. W.E. Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Arch. Gen. Psychiatry 21 (1969) 486-496
15. Goodwin F.K., Murphy D.L., Dunner D.L., and Bunney Jr. W.E. Lithium response in unipolar versus bipolar depression. Am. J. Psychiatry 129 (1972) 44-47
16. Gyulai L., Bowden C.L., McElroy S.L., Calabrese J.R., Petty F., Swann A.C., Chou J.C., Wassef A., Risch C.S., Hirschfeld R.M., Nemeroff C.B., Keck Jr. P.E., Evans D.L., and Wozniak P.J. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28 (2003) 1374-1382
17. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., and Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002) 530-537
18. McElroy S., Young A., Carlsson A., Olausson B., Nordenhem A., Paulsson B., and Brecher M. A double-blind, placebo-controlled study with acute and continuation phases of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Presented at the 3 rd Biennial Conference of the International Society for Bipolar Disorders, January 27-30, 2008, Delhi, India (2008)
19. Muzina D.J., Ganocy S., Khalife S., Gao K., Kemp D., Bachtel M.B., Colangelo E., Conroy C., Bilali S., and Calabrese J.R. A double-blind, placebo-controlled study of divalproex extended-release in newly-diagnosed mood stabilizer naive patients with acute bipolar depression. Presented at the 48th Annual New Clinical Drug Evaluation Unit Meeting (NCDEU), May 2008, Phoenix, AZ (2008)
20. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., and Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60 (2003) 261-269
21. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Leon A.C., Solomon D.A., Coryell W., Maser J.D., and Keller M.B. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 62 (2005) 1322-1330
22. Mendels J. Lithium in the treatment of depression. Am. J. Psychiatry 133 (1976) 373-378
23. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., and Kessler R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64 (2007) 543-552
24. Noyes Jr. R., Dempsey G.M., Blum A., and Cavanaugh G.L. Lithium treatment of depression. Compr. Psychiatry 15 (1974) 187-193
25. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell. Mol. Life Sci. 64 (2007) 2090-2103
26. Sachs G.S., Collins M.A., Altshuler L.L., Ketter T.A., Suppes T., Rasgon N.L., Frye M.A., and Wozniak P. Divalproex sodium versus placebo in the treatment of bipolar depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, December 8, 2001, San Juan, Puerto Rico (2001)
27. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., and Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. NEJM 356 (2007) 1711-1722
28. Shiah I.S., Yatham L.N., Lam R.W., and Zis A.P. Effects of divalproex sodium on 5-HT1A receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 17 (1997) 382-390
29. Suppes T., Datto C., and Minkwitz M. Effectiveness of the new extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (trial D144CC00002). Presented at the 161st Annual Meeting of the American Psychiatric Association, May 3-8, 2008, Washington, DC (2008)
30. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., and Calabrese J.R. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26 (2006) 600-609
31. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., MacQueen G., McIntyre R., Sharma V., Silverstone P., Alda M., Baruch P., Beaulieu S., Daigneault A., Milev R., Young L.T., Ravindran A., Schaffer A., Connolly M., and Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 7 Suppl 3 (2005) 5-69
32. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., MacQueen G., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Young A.H., Alda M., Milev R., Vieta E., Calabrese J.R., Berk M., Ha K., and Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 11 (2009) 25-55
33. Young A.H., McElroy S., Chang W., Olausson B., Paulsson B., and Brecher M. A double-blind, placebo-controlled study with acute and continuation phase in adults with bipolar depression (EMBOLDEN I). Presented at the 3 rd Biennial Conference of the International Society for Bipolar Disorders, January 27-30, 2008, Delhi, India (2008)